TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Outpatient Participant Mobility Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Required Wound Dressing Changes - Inpatient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Number of Required Wound Dressing Changes - Outpatient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Position of Hartmann's pouch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response assessment in neuro oncology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Canadian Occupational Performance Measurement (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Eye Gaze Technology Software Scoring: Insight Software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Visual Impairment Range (CVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effect on ischemic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of dose-limiting (DLT) toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in level of tissue water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Tau-217 protein value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with an Hb increase of ≥ 2 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bile leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Progression/Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Collection of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients related with Respiratory rate and SpO2 saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in depression level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Cesarean section in labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Occurrence of Uterine Hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to the prescribed medical treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Type of Lower Extremity Somatic Dysfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of PLwO who made serious weight loss effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pre-operative computed tomographic perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative computed tomographic perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration of computed tomographic perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized bleeding rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in muscle strength (Isometric knee extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood and blood component transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in 24-hour urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Range (%TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in The Neonatal Infant Pain Scale (NIPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability of difficult airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, C-SSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight after 1 year compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aspartate aminotransferase (AST) level and Alanine aminotransferase (ALT) level after 1 year compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in platelet count after 1 year compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in waist circumference and hip circumference after 1 year compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total fat percentage and visceral fat percentage after 1 year compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of procedures with clinical improvement of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of procedures with clinical improvement of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reaction Time Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Successful placement of the Zenflow Spring Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events (AE), serious adverse events (SAE) and adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: changes in anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge retention of correct c-collar application
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum gamma-glutamyltransferase (GGT) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient autonomy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 wild-type peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 alpha variant peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 beta variant peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 delta variant peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-care behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Distance Walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PODSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fluid overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Efficacy Towards Service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mental Health-related Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Views of Empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress-induced changes in mood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Contraceptive induced changes in average mood during transition phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Scale for Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of tooth movement (canine retraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleepiness problems
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Depression, anxiety and Stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of stay at the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decline in renal concentration ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cerebral Performance Category (CPC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: tumor remission status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall survival correlation with risk-stratification using ChromoSeq
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival correlation with risk-stratification using ChromoSeq
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of cases with new genetic information from ChromoSeq
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of regular menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in kyphosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance (SLHD test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance (side hop test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain via pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Nurses' Alarm Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in pigmentation area and color depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the incidence and hardness of fibrous induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the area of congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Vocal cords appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with CIDP who Experienced Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Change in Maximum Grip Strength in the More Affected Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained motivation for intervention activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Availability of genomic test results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain intensity measured by Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle strength measured by hand held dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOTTIP gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate of Partial Response or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with serum HDV RNA below detection or decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 2-hour Blood Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Static Standing Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HMI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Becks anxiety inventory (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 18F-LNC1007 injection
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate to CLAG regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the number of fully autonomous bowel movements per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of failure weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death or non-fatal acute myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rate of grade 3 or 4 treatment related adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (ORR) after treated by CAR-T treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Diagnostic Infant and Preschool Assessment at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Infant and Preschool Assessment at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active travel habits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adjacent segment disc degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cannabis withdrawal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Straight Leg Raise for Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Knee Extension Test for Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in processing speed scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: sore throat level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diet diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral hygiene practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total physiological complete response (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Joint Bleeding Rate (AJBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight and Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body distribution of 89Zr-Df-crefmirlimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of 89Zr-Df-crefmirlimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour tracer uptake with immune cell CD8 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in tumour volumetry, mpMRI parameters and MRI based texture metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of CGM for postpartum dysglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of subjects alive without mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Roland-Morris disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of cases with identified genetic disease or novel variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability assessment (Incidence of Treatment-Emergent Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Relative abundance of Bifidobacterium in the gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of spills of excretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentile-BMI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in knee range-of-motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postpartum Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnosis of Malabsorption Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of serum Beta-hydroxybutyrate (BHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in resistance to use of tobacco products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Lead Time Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with adequate CD86 receptor occupancy saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence rate of Immediate Adverse Reaction (IAR)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence rate of solicited local and systemic AE
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence rate of unsolicited AE
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence rate of SAEs, MAAEs, AESIs
Endpoint domain: Adverse events/effects
Primary endpoint: GMT of Anti-SAS-CoV-2 RBD IgG measured with ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in geometric mean titer of IgGs specific to S protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in geometric mean titer of neutralizing antibodies to SARS-Cov-2 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of groups constituted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under curve zero to time infinity (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of PI-RADS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge of caring for LBT+ patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: attitudes toward caring for LBT+ patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-confidence levels in caring for LBT+ patients
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Prevalence of childbirth-related PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of referrals to emergency departments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Any-cause mortalities
Endpoint domain: Mortality/survival
Primary endpoint: Degree of PSMA uptake by HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFM-32 responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with wound appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with back
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence Rate of Breakthrough Cases of SARS-CoV-2 Infection
Endpoint domain: Mortality/survival
Primary endpoint: Time to SARS-CoV-2 Breakthrough Infection
Endpoint domain: Mortality/survival
Primary endpoint: TEWL measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes